NuSep tries NxGen
Thursday, 02 October, 2008
Bioseparations company NuSep [ASX: NSP] has reached a binding agreement to acquire NxGen Pharmaceuticals for $25 million.
Pending shareholder approval, NuSep will acquire all of NxGen in exchange for 294 million NuSep shares valued at 8.5c each.
This represents 87.5 per cent of NuSep's expanded capital and 10 times NxGen's net profit forecast for this financial year.
NxGen is a custom pharmaceuticals manufacturer and formulator, with products including an erectile dysfunction nasal spray it makes for a medical clinic.
Potential biological targets for vascular dementia
Caused by damage to blood vessels in the brain, there is currently no approved treatment for...
Ecopha Biotech announces strategic cross-border model
To commercialise its ecopha.bio technology for a Pongamia-based bioeconomy, Australian company...
Could this 'virus-tearing' plastic film protect hospital equipment?
A thin plastic film that tears apart viruses on contact could help protect high-touch hospital...
